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Abstract 
Background: Pooled human platelet lysate (pHPL) is an efficient alternative to xenogenic supplements for ex vivo 
expansion of mesenchymal stem cells (MSCs) in clinical studies. Currently, porcine heparin is used in pHPL‑supple‑
mented medium to prevent clotting due to plasmatic coagulation factors. We therefore searched for an efficient and 
reproducible medium preparation method that avoids clot formation while omitting animal‑derived heparin.
Methods: We established a protocol to deplete fibrinogen by clotting of pHPL in medium, subsequent mechanical 
hydrogel disruption and removal of the fibrin pellet. After primary culture, bone‑marrow and umbilical cord derived 
MSCs were tested for surface markers by flow cytometry and for trilineage differentiation capacity. Proliferation and 
clonogenicity were analyzed for three passages.
Results: The proposed clotting procedure reduced fibrinogen more than 1000‑fold, while a volume recovery of 
99.5 % was obtained. All MSC types were propagated in standard and fibrinogen‑depleted medium. Flow cytometric 
phenotype profiles and adipogenic, osteogenic and chondrogenic differentiation potential in vitro were independent 
of MSC‑source or medium type. Enhanced proliferation of MSCs was observed in the absence of fibrinogen but pres‑
ence of heparin compared to standard medium. Interestingly, this proliferative response to heparin was not detected 
after an initial contact with fibrinogen during the isolation procedure.
Conclusions: Here, we present an efficient, reproducible and economical method in compliance to good manufac‑
turing practice for the preparation of MSC media avoiding xenogenic components and suitable for clinical studies.
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Background
The isolation and ex  vivo expansion of mesenchymal 
stem cells (MSCs) is a prerequisite for clinical evaluation 
regarding their promotion of various therapeutic effects 
such as tissue regeneration, neuroprotection or immu-
nomodulation [1, 2]. Cell culture media used for in vitro 
expansion frequently contain fetal bovine serum (FBS) as 
a source of growth factors. Even though widely applied, 
major concerns regarding the use of animal serum have 
emerged: Bovine serum harbors the risk of xenogenic 
immune reactions. Human MSCs cultured in FBS were 
shown to generate immune responses in patients receiv-
ing MSC-based therapies [3–5]. This might be due to 
bovine proteins, that were shown to be internalized 
either directly into the cells [6] or transferred by bovine 
extracellular vesicles [7]. Furthermore, pathogens such 
as viruses, mycoplasma and prions can be transmit-
ted by animal sera [8–11]. In addition, bovine sera vary 
from batch to batch with regard to their effectiveness to 
Open Access
*Correspondence:  e.rohde@salk.at 
†Sandra Laner‑Plamberger and Thomas Lener contributed equally to this 
work
2 Department of Blood Group Serology and Transfusion Medicine, Spinal 
Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus Medical 
University, Lindhofstrasse 20‑22, 5020 Salzburg, Austria
Full list of author information is available at the end of the article
Page 2 of 10Laner‑Plamberger et al. J Transl Med  (2015) 13:354 
support cell proliferation [12, 13]. Because of these con-
cerns, the use of FBS in human cell culture applied for 
stem cell therapies is not recommended to date [14, 15]. 
Thus, a growing demand for human alternatives such as 
pooled human platelet lysate (pHPL) has emerged for 
clinical trials investigating MSCs [16]. pHPL contains 
abundant growth factors and cytokines to efficiently 
boost MSC proliferation in vitro [17, 18]. Further, pHPL 
components include plasmatic coagulation factors such 
as fibrinogen and various platelet-derived factors [19, 20]. 
As a result of physiological coagulation, pHPL added to 
calcium-containing growth media rapidly form viscoe-
lastic fibrin gels. To prevent clot formation in cell cul-
ture, heparin, a highly sulfated glycosaminoglycan [21], is 
commonly added. It has been shown that the concentra-
tion and quality of heparin, usually of porcine origin, and 
the added preservatives therein are critical for cell culture 
with respect to proliferation, colony forming and ex vivo 
differentiation capacity of mesenchymal stem cells, but 
also various other cell types [22–27]. Data further indi-
cate that heparin disrupts the CXCR4/SDF-1 signaling 
axis and may interfere with migration and homing capac-
ity of BM-derived mononuclear cells [28]. Therefore 
it has been suggested that heparin should be supplied 
at lowest possible concentrations in media containing 
pHPL to prevent gel formation [26]. It may be not only 
beneficial to avoid heparin, but also to deplete fibrino-
gen which is a known pro-inflammatory component of 
pHPL [29]. A recent study demonstrated that fibrinogen 
increases the adhesion of peripheral blood human natu-
ral killer cells, which in turn stimulate human BM-MSC 
invasion and may not only induce tissue repair but also 
an exacerbated inflammatory response [29]. Recent data 
suggest that fibrinogen may negatively affect the immune 
modulating capacity of MSCs [30]. Considering numer-
ous clinical trials for the treatment of immune disorders, 
fibrinogen-depletion in pHPL-containing growth media 
is potentially useful. To date procedures to reduce fibrin-
ogen and to avoid heparin are based on the addition of 
CaCl2 to undiluted pHPL to antagonize citrate effects 
and to induce the coagulation cascade, thus producing 
serum-converted platelet lysate [30, 31].
In our study, we searched for alternative methods to 
deplete fibrinogen in pHPL-supplemented media while 
preventing the use of any additional reagents such as 
CaCl2 or porcine heparin. Fibrin polymers rapidly assem-
ble by a modified polycondensation reaction from fibrin-
ogen resulting in three-dimensional networks with large 
elastic moduli [32, 33]. Owing to the hydration and the 
physical properties of viscoelastic fibrin polymer gels, 
the networks are sensitive to strain and excessive strain 
burden causes the collapse and aggregation of the fibrin 
fibers. We have applied a strategy based on this fibrin gel 
physics to remove fibrinogen from pHPL-based cell cul-
ture media without additional requirement for further 
chemical support. Following our protocol, the resulting 
complete growth medium remains clear and no further 
gel or fiber formation is observed. Here we show that 
heparin free and fibrinogen depleted media are equally 
efficient to standard pHPL media containing heparin 
for the cultivation of human MSCs. The here described 
method is the first to gain entirely humanized cell culture 
media with high medium recovery rates after induced 
clotting and low remaining fibrinogen amounts. Thus, it 
facilitates a standardized and GMP-grade generation of 
medium for future clinical studies.
Methods
Medium preparation, fibrinogen depletion 
and quantification
Three different media were prepared (medium A, B, 
C) using alpha-modified Minimum Essential Medium 
Eagle (αMEM M4526, Sigma Aldrich, St. Louis, MO, 
USA) supplemented with 10 % pHPL and 5.5 mM (N2)-
L-Alanyl-L-Glutamin (Dipeptiven, Fresenius Kabi, Graz, 
Austria). pHPL was produced as described with minor 
modifications [18]. In brief we used outdated buffy-coat 
derived platelet concentrates (PCs) prepared from regular 
healthy blood donors at the Department for Transfusion 
Medicine. For each batch five PCs blood group O were 
pooled with five PCs blood group A or B. Platelet lysis 
was induced by several freeze/thaw steps (−30 °C/37 °C) 
and platelet fragments were depleted by centrifugation 
(4000×g, 15 min). Suitable aliquots were stored at −30 °C 
until use. Dipeptiven was used due to long-lasting stabil-
ity in culture medium compared to standard L-Glutamin. 
Medium A (+fibrinogen/+heparin) was prepared as pre-
viously described [18] with 2  IU/mL of stabilisator-free 
porcine heparin (Biochrom, Berlin, Germany) to prevent 
clotting (Fig. 1, white bars) and is referred to as standard 
medium. Media B and C were produced by intentional 
hydrogel formation after pHPL supplementation in the 
absence of heparin. After transferring the supplemented 
αMEM to 50  mL conical tubes, hydrogel formation was 
allowed during an incubation for 4  h at room tempera-
ture (RT) followed by overnight (o/n) incubation at 4 °C. 
Finally the coagulated medium was heated to 37 °C (1 h) to 
allow complete fibrin clotting. The collapse after hydrogel 
formation was induced by vigorous shaking of the conical 
tubes followed by a centrifugation step (10 min at 3000×g, 
RT). The resulting clear medium supernatant was filtered 
through a 0.22 µm filter (Merck Millipore, Billerica, MA, 
USA). While medium B (−fibrinogen/−heparin, Fig.  1, 
grey) remained without further supplement, medium C 
(−fibrinogen/+heparin, Fig.  1, black) was supplemented 
with 2 IU/mL of heparin. After fibrinogen depletion, the 
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volume recovery of media B and C was measured. The 
concentration of residual fibrinogen was determined in 
quadruplicate for three independent medium prepara-
tions by ELISA (Abcam, Cambridge, UK) according to the 
manufacturer’s instructions.
Experimental setup, isolation and propagation of MSCs
The study was performed in accordance with the Helsinki 
Declaration. All donors signed an informed consent con-
cerning the research use of the donated whole blood for 
pHPL production and of donated umbilical cord (UC) 
or bone marrow (BM) tissue. UC-MSCs (n  =  10) and 
BM-MSCs (n = 3) were isolated as described previously 
[16, 34, 35]. Antibiotics (100  mg/mL streptomycin and 
62.5  mg/mL penicillin, LifeTechnologies, Carlsbad, CA, 
USA), were used for initial isolation of UC-MSCs only 
and removed after the first 48 h. All subsequent culture 
conditions lacked antibiotics and cells were cultured at 
37 °C, 5 % CO2 and 95 % humidity.
UC-MSCs of five independent donations (group 1, Fig. 2) 
were initially isolated using standard medium A only. 
Another five donations (group 2) were immediately sepa-
rated into three cord pieces and differentially isolated in 
either medium condition A, B or C. We further compared 
the functional response of UC-MSCs to various media 
types with BM-MSCs (group 3). Because we regularly col-
lected BM-aspirates using heparin, we took BM-MSCs 
formerly isolated in standard medium A (corresponding to 
UC-MSCs group1) as controls. After expansion, all MSCs 
were characterized by flow cytometric analysis and differen-
tiation assays as well as by proliferation and colony forming 
unit (CFU) assays over three subsequent passages (Fig. 2).
Flow cytometric analysis
MSCs were incubated in blocking buffer (5  % sheep 
serum (Eubio, Vienna, Austria) in PBS) in the dark at 4 °C 
for 25  min. Cells were stained with fluorescein isothyo-
cyanate (FITC), phycoerythrin (PE) or allophycocyanin 
(APC)-conjugated mouse anti-human antibodies and 
corresponding isotype controls (Table 1) in flow cytom-
etry buffer (PBS and 2 % FBS) at 4 °C in the dark for 25 
min. Cells were washed, and analyzed using a FC500 flow 
cytometer (Beckman Coulter, Brea, CA, USA). A mini-
mum of 10,000 nucleated cells was acquired and data 
were analyzed with FlowJo software (Vers. 7.6; TreeStar 
Inc., Ashland, OR, USA).
Differentiation assays
The adipogenic, osteogenic and chondrogenic differen-
tiation potential of group 1 and group 2 UC-MSCs and 
BM-MSCs (group 3) was tested after expansion in the 
particular medium type used for the primary isolation 
(adipogenic differentiation: passage  =  2, osteogenic 
and chondrogenic differentiation: passage  =  3). For 
osteogenic and adipogenic differentiation, 1000 BM- or 
UC-MSCs/cm2 were seeded. After 24  h, medium was 
replaced by differentiation medium as described [36]. 
At day 21, cells were fixed using 4  % paraformaldehyd 
(PFA, Sigma Aldrich) and stained with either 0.5  % 
Alizarin Red (Sigma Aldrich) or 1  % Sudan III (Sigma 
Aldrich). Chondrogenic differentiation was induced 
using 250,000 cells per pellet cultivated in hMSC chon-
drogenic SingleQuots (Lonza, Basel, Switzerland) in 
the presence of TGF-β3 (20 µg/mL) for 21 days. Pellets 
were harvested by centrifugation (1500×g for 5  min), 
fixed in 4 % PBS buffered formalin and paraffin-embed-
ded. After deparaffination of 2  µm sections in graded 
alcohols, 1 % Alcian Blue staining solution (8GS, Gatt-
Koller, Absam, Austria) and Nuclear Fast Red solution 
(Sigma Aldrich) was applied for 15  min (Multistainer 
platform, Leica, Wetzlar, Germany). Photographs were 
taken using a PrimoVert Light microscope equipped 
Fig. 1 Production of standard medium (condition A), fibrinogen‑depleted medium without (condition B) and with heparin (condition C). To 
prepare standard medium A (white), αMEM was supplemented with 10 % pooled human platelet lysate (pHPL), 5.5 mM Dipeptiven and 2 IU/mL 
heparin. Medium B (grey) and C (black) were prepared by supplementing αMEM with 10 % pHPL and 5.5 mM Dipeptiven and by allowing clot 
formation over night (o/n) followed by mechanical disruption of the fibrin gel by vigorous shaking. After removal of the fibrin pellet medium B was 
ready to use, while medium C was additionally supplemented with 2 IU/mL heparin
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with an AxioCam ERc5  s digital camera (both from 
Zeiss, Oberkochen, Germany).
Proliferation and colony forming unit (CFU) assays
To test proliferation, 1300 UC-MSCs/cm2 and 3300 
BM-MSCs/cm2 were seeded in all three medium 
types. After 96  h, cell number was determined using 
“Neubauer improved” counting chambers (C-Chip, 
Biochrom). Cell growth was evaluated by total cell 
counts and cumulative population doublings (cPD) by 
means of the formula ln(N)/ln(2), where N is the cell 
number of detached cells divided by the number of 
cells seeded [37]. To investigate colony forming capac-
ity, 3 MSCs/cm2 were seeded in cell culture dishes and 
cultured for 14 days. Colonies were fixed in 4 % PFA 
(Sigma Aldrich) and stained with 0.05 % Crystal Violet 
(Sigma Aldrich). Colonies were counted visually. Each 
assay was done in triplicate over three subsequent 
passages (BM-MSCs: passages 2–4, UC-MSCs: pas-
sages 1–3).
Fig. 2 Experimental workflow: Isolation and characterization of umbilical cord (UC‑) and bone marrow (BM‑) MSCs. UC‑MSCs group 1 (left) and BM‑
MSCs, group3 (right) were isolated using medium condition A exclusively. UC‑MSCs group 2 (middle) were isolated in all three medium conditions 
(A, white; B, grey and C, black). After isolation and expansion, all MSC types tested by flow cytometric analysis and differentiation assays. Proliferation 
and colony forming unit assays (CFU) were performed independently in triplicates over a minimum of seven population doublings (UC‑MSCs: pas‑
sages 1–3, BM‑MSCs: passages 2–4) examining all three medium types (A, B and C)
Table 1 Antibodies used for flow cytometric analysis of isolated UC- and BM-MSCs
Antibody Conjugate Company Clone
Anti HLA‑DR (MHC II) FITC Becton Dickinson, Franklin Lakes, NJ, USA L243 
Anti‑h/m/rNG2/MCSP PE R&D Systems, McKinley Place, MN, USA LHM‑2
CD105 APC Caltag Laboratories, Carlsbad, CA, USA SN6
CD14 PE‑Cy7 Becton Dickinson MdeltaP9
CD140b PE Becton Dickinson 28D4
CD144 (VE‑Cadherin) APC BioLegend, San Diego, CA, USA BV9
CD19 FITC Becton Dickinson SJ25C1
CD271 PE Becton Dickinson C40‑1457
CD31 FITC Becton Dickinson WM59
CD34 PE Becton Dickinson 8G12
CD45 APC Becton Dickinson HI30
CD73 PE Becton Dickinson AD2
CD90 FITC Immunotech, Quebec, Canada F15‑42‑1‑5
Mouse IgG1 FITC Becton Dickinson X40
Mouse IgG1 PE Becton Dickinson X40
Mouse IgG1 APC Becton Dickinson X40
Mouse IgG2a PE Becton Dickinson X39
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Statistical analysis
Data are presented as arithmetic mean ± standard devia-
tion (SD). Data were compared using 2-way ANOVA and 
Bonferroni multiple comparison test. Significant results 
are signed by asterisks (p < 0.001 or p < 0.05). Analysis 
was done with GraphPad Prism 5 (GraphPad Software, 
La Jolla, CA, USA).
Results
Mechanical clot depletion results in significant reduction 
of fibrinogen and high rates of media volume recovery
Following hydrogel formation, disruption and centrifu-
gation, the filtration step resulted in a clear and liq-
uid medium without delayed fibrin precipitation over 
4  weeks. Measurement of fibrinogen levels in standard 
(medium A) compared to fibrinogen-depleted media (B 
and C) showed an efficient reduction from 70,935  ng/
mL starting concentration to more than 1000-fold lower 
fibrinogen levels (66.2 and 64.5  ng/mL, respectively, 
Fig.  3). After clot formation and centrifugation the vol-
ume recovery was 99.5 ± 0.2 % (n = 10).
Phenotype and in vitro functionality of human UC‑ 
and BM‑MSCs are independent of fibrinogen and heparin
Flow cytometry of UC-MSCs initially isolated in standard 
medium (group 1), of differentially isolated UC-MSCs 
(group 2) and of BM-MSCs (group 3) revealed a consist-
ent surface protein expression pattern (CD73+/90+/105+/
NG-2+ and CD14−/19−/31−/34−/45−/144−/271−/HLA-
DR−) characteristic for MSCs (Fig. 4a–c). Discrete vari-
ations in surface marker expression were attributed to 
donor variability, but were independent of medium con-
ditions during isolation and propagation (Additional 
file  2: Figure S2). Tri-lineage differentiation potential 
evaluation showed no major differences between cell 
and medium types. Following adipogenic induction, 
BM-MSCs showed more and larger lipid droplets com-
pared to both UC-MSC groups (Fig. 4d–f, upper panel). 
All MSCs showed comparable chondrogenic differen-
tiation potential as demonstrated by Alcian Blue staining 
(Fig.  4d–f, lower panel). No variations in differentiation 
potential were observed within UC-MSC group 2: inde-
pendent of medium condition A, B or C UC-MSCs dem-
onstrated comparable tri-lineage differentiation potential 
(data not shown).
Heparin increases proliferation of UC‑ MSCs in the absence 
of fibrinogen
Proliferation assays performed with the three different 
medium conditions (A, B or C) revealed no significant 
differences between the cell counts of UC-MSCs group 
1 and BM-MSCs (group 3) that had been exclusively iso-
lated in standard medium A (Fig. 5a and Additional file 1: 
Figure S1). UC-MSCs (group 2) initially isolated and fur-
ther propagated either in the presence (medium A) or in 
the absence of both, fibrinogen and heparin (medium B) 
showed similar proliferative activity compared to UC-
MSCs group 1 and BM-MSCs (group 3). After primary 
isolation of UC-MSCs in medium C, the persistent pres-
ence of heparin in fibrinogen-depleted medium resulted 
in a sustained and pronounced proliferative response 
(Fig.  5a and Additional file  1: Figure S1). These results 
were partially mirrored in CFU assays (Fig. 5b, c). While 
the total cell counts reached similar levels as compared to 
UC-MSCs group 1 the corresponding CFU numbers were 
reduced in UC-MSC group 2 propagated in standard 
medium A (fib+/hep+). A similar, but more pronounced 
effect was observed for BM-MSCs: While colony number 
was reduced, the total cell count was comparable with 
UC-MSC group 1. This could be attributed to the high 
proliferative activity of single clones resulting in larger 
colony sizes (and higher cell numbers per colony). One 
obvious difference was the consistently weak Crystal Vio-
let staining that was found with BM-MSCs as compared 
to UC-MSCs. However cell density per colony was high, 
thus MSC counts reached comparable levels to UC-MSC 
group 1 (Fig. 5c).
These data point to a significant mitogenic effect of 
heparin on primary UC-MSCs, when isolated and per-
manently cultured in the absence of fibrinogen. However, 
if MSCs had former contact with fibrinogen (UC-MSC 
group 1 and BM-MSC, group 3) this response to heparin 
was not observed, suggesting that the mitogenic effect of 
heparin might be masked by fibrinogen.
Discussion
Human MSCs are key candidates for cell therapy with 
the intention to treat immune disorders like graft-ver-
sus-host disease, or multiple sclerosis, inherited tissue 
Fig. 3 Quantitative ELISA reveals efficient depletion of fibrinogen. 
Quantitative ELISA demonstrated that fibrinogen concentration in 
depleted media B and C is 1000‑fold lower compared to standard 
medium A. Data shown are mean values of three independent 
medium preparations measured in quadruplicates ± standard devia‑
tion (SD). The significance level is indicated by asterisks (* p < 0.001)
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defects such as osteogenesis imperfecta and traumatic, 
toxic or ischemic organ damage [38–41]. Animal com-
ponents are not recommended to be used in clinical 
trials and can be replaced by pHPL derived from human 
platelet rich plasma (PRP) [17, 18]. To avoid unin-
tended clot formation of plasmatic coagulation factors 
Fig. 4 MSCs display characteristic immunophenotype and trilineage differentiation potential independent of medium type. Flow cytometric analy‑
sis of UC‑MSCs, group 1 (a), UC‑MSCs, group 2 (b) and BM‑MSCs, group3 (c) revealed comparable immunophenotype profiles: CD73+/90+/105+/
NG‑2+ and CD14−/19−/31−/34−/45−/144−/271−/HLA‑DR−. Histogram plots show representative results of UC‑MSCs, group 1 consistently propa‑
gated in medium A (+fib/+hep), UC‑MSCs, group 2 in medium C (−fib/+hep) and BM‑MSCs, group 3 in medium A. d–f UC‑ and BM‑MSCs display 
a similar in vitro trilineage potential for adipogenic (Sudan III staining), osteogenic (Alizarin Red staining) and chondrogenic (Alcian Blue staining, 
Nuclear Fast Red (NFR) staining) differentiation compared to controls. Total magnification: 200× adipogenic differentiation, 100× osteogenic dif‑
ferentiation, 40× and 100× chondrogenic differentiation
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in pHPL-supplemented medium, the addition of por-
cine-derived heparin is commonly used. Although por-
cine heparin has been clinically applied for decades, 
some reports have pointed out severe side effects such 
as thrombocytopenia, hyperkalemia and hypersensitiv-
ity in up to 5 % of the patients, which is ascribed either 
to the product itself, the impurities contained within the 
product or the type of preparation [42–48]. Attempts to 
produce heparin by chemoenzymatic synthesis have been 
reported and may help to avoid the porcine product in 
human cell culture [49]. However, even if synthesized 
successfully it would be necessary to demonstrate similar 
in vivo and in vitro effects of synthetic heparin on MSC 
functionality, such as immunomodulatory potential, 
stemness and proliferative, migratory as well as homing 
capacity [28, 30, 50, 51].
In order to avoid the addition of heparin, work from 
Copland et al. and Mojica-Henshaw et al. suggested the 
reduction of heparin and also of fibrinogen from com-
plete cell culture growth media formulations [30, 31]. 
Their proposed strategy used forced gelation of platelet 
lysate by addition of CaCl2 prior to cell culture medium 
supplementation. This method may be limited by (1) non-
physiologic calcium levels, that in turn may negatively 
influence the osteogenic properties of MSCs [52], and (2) 
by poor volume recovery of fibrinogen-depleted platelet 
lysate. Only 60 % of the HPL starting volume was recov-
ered after the clotting procedure by Copland et al. [30]. 
The method presented in this study allows clot formation 
of pHPL supplemented medium and achieves a 99.5  % 
medium recovery rate, while achieving a more than 1000-
fold fibrinogen reduction. In contrast to protocols that 
Fig. 5 Proliferation and colony forming capacity of UC‑ and BM‑derived MSCs. a The proliferative capacity of UC‑MSCs, group 1 (left) and of 
BM‑MSCs, group 3 (right) is comparable in the presence and absence of fibrinogen and heparin. UC‑MSCs, group 2 (middle) show significantly 
enhanced mitogenic response to heparin if consistently isolated and cultivated in presence of heparin in fibrinogen‑depleted medium (medium 
C) compared to standard medium A (+fib/+hep). All data shown are mean values of total cell counts of three subsequent passages done in tripli‑
cates ± standard deviation (SD) of five (UC‑MSCs, group 1 and group 2) or three (BM‑MSCs, group 3) independent donors. b UC‑MSCs, group 1 (left) 
show equal colony forming capacity independent of the medium type used. Number of CFUs in UC‑MSCs, group 2 (middle) is comparable between 
medium A (+fib/+hep) and B (−fib/−hep), but significantly enhanced in the presence of heparin (medium C; −fib/+ hep). Colony count of BM‑
MSCs, group 3 was reduced in comparison to UC‑MSCs but independent of media conditions. Data shown are mean values of total colony counts 
of three subsequent passages done in triplicates ± standard deviation (SD). The significance level is indicated by asterisks (* p < 0.05). c UC‑MSCs, 
group 1 showed smaller and more colony forming units compared to UC‑MSCs, group 2 and BM‑MSCs, group 3. CFU numbers of UC‑MSC group 1 
and BM‑MSCs were independent of the medium type used for MSC isolation and cultivation. UC‑MSC group 2 showed significantly more colonies 
in medium C (−fib/+hep), as compared to standard medium A (+fib/+hep) and medium B (−fib/−hep). Images show representative colonies of 
each MSC group, all passage = 2
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suggest a minimum concentration of heparin (0.6  IU/
mL) [26], our heparin-free method represents a robust 
procedure resulting in a clear cell culture medium with-
out delayed further clotting or fibrin precipitation. The 
method can be performed in a highly standardized man-
ner, omits the addition of nonessential reagents, facili-
tates an economic use of pHPL as human alternative 
to FBS and thus provides an efficient and reproducible 
preparation of complete cell culture growth medium.
pHPL as an alternative to FBS is increasingly used in 
the scientific community and is under investigation as an 
important supplement in fully humanized culture systems 
for the generation of cellular therapeutics. It is regarded 
as rather safe concerning infectious diseases due to the 
routinely tested infectious parameters (for most Euro-
pean blood centers: HIV1/2, HAV, HBV, HCV, TPHA and 
Parvo B19). However, there is a certain risk of transmit-
ting viruses that are not routinely tested in blood donors. 
Therefore, in 2014 Castiglia et  al. suggested to subject 
pHPL to pathogen inactivation (iHPL) by psoralen and 
showed that there were no significant differences between 
pHPL and iHPL concerning colony-forming unit number, 
immunophenotype or multipotent capacity of BM-MSCs 
[53]. However, the effect of psoralen on MSCs expanded in 
iHPL has not yet been investigated in more detail. Further 
studies are required to demonstrate the role of psoralen in 
cell culture of MSCs for clinical applications. In addition, 
there are reports about patients with allergic reactions to 
psoralen [54]. In order to circumvent psoralen, pathogen 
inactivation can also be done with riboflavin in combina-
tion with UVA or using UVC only. However, several stud-
ies show that all of the pathogen inactivating treatments 
influence the proteome and activation states of platelets 
[55, 56]. This might impact on functionality of cell therapy 
products generated in iHPL. As an alternative, quality tests 
for a broad range of contaminating viruses, which are per-
formed on a non-routine basis, are discussed to ensure 
safety and purity of cell therapy products [57]. However, 
results of a risk-based analysis performed in our cell pro-
duction facility, an academic GMP-laboratory, did not 
argue for extended virus testing.
Analysis of the different media formulations for prolifer-
ative and functional support of UC-MSCs and BM-MSCs 
revealed no significant differences in proliferation, colony 
forming capacity, phenotype and in vitro tri-lineage differ-
entiation, if MSCs were isolated in the presence or absence 
of both, fibrinogen and heparin. In CFU assays we found 
higher colony numbers in UC-MSCs group 1 as compared 
to group 2 in standard medium, a difference which was not 
reflected in absolute cell counts. This effect can be assigned 
to donor variability with large size and enhanced cell den-
sity per colony compensating the observed difference in 
CFU numbers. Our findings support the assumption that 
fibrinogen-depletion does not result in a significant loss 
of various pHPL-supplied growth factors or components 
critical for adipo-, osteo- and chondrogenic induction. 
Therefore fibrinogen-depleted and heparin-free medium 
is suitable for the successful in vitro propagation of func-
tional MSCs, suggesting that both substances are dispen-
sable for the effective expansion of UC- and BM-MSCs.
However, we provide evidence that during isolation 
and further expansion of UC-MSCs, fibrinogen and hep-
arin do critically influence at least proliferative capac-
ity. UC-MSCs of the same donor primarily isolated and 
maintained in the absence of fibrinogen, but in the pres-
ence of heparin, showed an enhanced proliferation com-
pared to UC-MSCs initially isolated in standard medium. 
This proliferative response to heparin was never found 
after an initial contact to fibrinogen. The enhanced pro-
liferative effect of heparin on UC-MSCs isolated and cul-
tivated in fibrinogen-depleted medium indicates a strong 
mitogenic stimulus induced by heparin, which may be 
masked by fibrinogen. These results are in line with data 
suggesting that heparin may interfere with proliferation 
and functional capacity of MSCs [23, 26, 28, 50]. Further 
studies are needed to investigate the molecular mecha-
nism and a so far unknown interplay between fibrinogen, 
heparin and MSCs in vitro as well as putative effects on 
MSC functionality in vivo.
Conclusion
In conclusion, we have shown that porcine heparin is 
dispensable for the propagation of MSCs from umbilical 
cord and bone marrow. We have developed a convenient, 
reproducible and GMP-compliant procedure to deplete 
pHPL-derived fibrinogen in MSC culture medium that 
can be efficiently used for MSC propagation in clinical 
trials.
Additional files
Additional file 1: Figure S1. MSC proliferation shown as cumulative 
population doublings (cPD). cPD have been calculated. The proliferative 
capacity of UC‑MSCs, group 1 and of BM‑MSCs, group 3 is comparable 
in the presence and absence of fibrinogen and heparin. In contrast, 
cPD of group 2 UC‑MSCs show a significantly enhanced proliferation in 
response to heparin (group 2_C) compared to medium A and medium B. 
Data shown are mean values of cPD of three passages done in tripli‑
cates ± standard deviation (SD) of five (UC‑MSCs) or three (BM‑MSCs) 
independent donors.
Additional file 2: Figure S2. Flow cytometric analysis of individual 
MSC donations. Flow cytometric analysis of all individual donations 
of UC‑MSCs, group 1 (A), UC‑MSCs, group 2 (B) and BM‑MSCs, group 
3 (C). All MSCs isolated show a characteristic immunophenotype: 
CD73+/90+/105+/NG‑2+ and CD14−/19−/31−/34−/45−/144−/271−/
HLA‑DR−. No significant differences in surface marker expression could be 
observed if MSCs of the same donor were cultivated in different medium 
conditions (A, B or C); Minor variations in expression profiles were ascribed 
to donor variability.
Page 9 of 10Laner‑Plamberger et al. J Transl Med  (2015) 13:354 
Abbreviations
BM: bone marrow; BM‑MSCs: bone marrow‑derived mesenchymal stem cells; 
Fib: fibrinogen; GMP: good manufacturing practice; Hep: heparin; MSCs: Mes‑
enchymal stem cells; PC: platelet concentrate; pHPL: pooled human platelet 
lysate; UC: umbilical cord; UC‑MSCs: umbilical cord‑derived mesenchymal 
stem cells.
Authors’ contributions
SLP participated in the design of the study, carried out the isolation of UC‑
MSCs, performed the corresponding proliferation and CFU assays and all 
differentiation assays (UC‑MSCs and BM‑MSCs), did statistical analysis and 
drafted the manuscript. TL participated in the design of the study, carried out 
proliferation and CFU assays regarding BM‑MSCs and drafted the manuscript. 
SLP and TL did the analysis and interpretation of the data. DS performed flow 
cytometry and participated in analysis and interpretation of the data. DAS 
participated in the isolation of UC‑MSCs, performed proliferation and CFU 
assays regarding BM‑MSCs and did the statistical analysis. TS participated in 
MSC isolation and flow cytometry. MÖ did flow cytometry, provided pHPL and 
participated in data analysis. CHK performed histochemical staining and analy‑
sis of chondrogenic differentiation assays. TF and VRJ participated in study 
design, coordination of tissue donations and critically revised the manuscript. 
KS provided pHPL, participated in data interpretation and critically revised 
the manuscript. MG participated in study design, performed the isolation of 
BM‑MSCs, did analysis and interpretation of the data, drafted and critically 
revised the manuscript. ER participated in the study design and interpretation 
of the data, drafted the manuscript and gave final approval of the version to 
be published. All authors read and approved the final manuscript.
Author details
1 Spinal Cord Injury and Tissue Regeneration Center Salzburg, Paracelsus 
Medical University, Salzburg, Austria. 2 Department of Blood Group Serology 
and Transfusion Medicine, Spinal Cord Injury and Tissue Regeneration Center 
Salzburg, Paracelsus Medical University, Lindhofstrasse 20‑22, 5020 Salzburg, 
Austria. 3 Department of Pathology, Paracelsus Medical University, Salzburg, 
Austria. 4 Department of Gynecology and Obstetrics, Paracelsus Medical 
University, Salzburg, Austria. 
Acknowledgements
We thank Prof. Dr. Dirk Strunk (Institute of Experimental und Clinical Cell Ther‑
apy, Spinal Cord Injury and Tissue Regeneration Center Salzburg (SCI‑TReCS), 
Paracelsus Medical University, Salzburg) and Dr. Andreas Reinisch (Institute for 
Stem Cell Biology and Regenerative Medicine (ISCBRM), Stanford University, 
CA) for fruitful discussion, the midwife team of the Department of Gynecol‑
ogy and Obstetrics, Paracelsus Medical University, Salzburg, for their support 
and Nina Held, Nicole Kerschbaumer and Brian van Merkestijen for excellent 
technical assistance. This work was supported by the Spinal Cord Injury and 
Tissue Regeneration Center Salzburg (SCI‑TReCs).
Competing interests
The authors declare that they have no competing interests.
Received: 27 August 2015   Accepted: 29 October 2015
References
 1. Wang S, Qu X, Zhao RC (2012) Clinical applications of mesenchymal stem cells. 
J Hematol Oncol 5:19. doi: 10.1186/1756‑8722‑5‑19 (1756-8722-5-19 [pii]).
 2. Glenn JD, Whartenby KA. Mesenchymal stem cells: emerging 
mechanisms of immunomodulation and therapy. World J Stem Cells. 
2014;6(5):526–39. doi:10.4252/wjsc.v6.i5.526.
 3. Selvaggi TA, Walker RE, Fleisher TA. Development of antibodies to fetal 
calf serum with arthus‑like reactions in human immunodeficiency 
virus‑infected patients given syngeneic lymphocyte infusions. Blood. 
1997;89(3):776–9.
 4. Mackensen A, Drager R, Schlesier M, Mertelsmann R, Lindemann A. Pres‑
ence of IgE antibodies to bovine serum albumin in a patient developing 
anaphylaxis after vaccination with human peptide‑pulsed dendritic cells. 
Cancer Immunol Immunother. 2000;49(3):152–6.
 5. Tuschong L, Soenen SL, Blaese RM, Candotti F, Muul LM. Immune 
response to fetal calf serum by two adenosine deaminase‑deficient 
patients after T cell gene therapy. Hum Gene Ther. 2002;13(13):1605–10. 
doi:10.1089/10430340260201699.
 6. Spees JL, Gregory CA, Singh H, Tucker HA, Peister A, Lynch PJ, et al. 
Internalized antigens must be removed to prepare hypoimmuno‑
genic mesenchymal stem cells for cell and gene therapy. Mol Ther. 
2004;9(5):747–56. doi:10.1016/j.ymthe.2004.02.012.
 7. Shelke GV, Lasser C, Gho YS, Lotvall J. Importance of exosome deple‑
tion protocols to eliminate functional and RNA‑containing extracellular 
vesicles from fetal bovine serum. J Extracell Vesicles. 2014;3. doi:10.3402/
jev.v3.24783 24783 [pii].
 8. Nuttall PA, Luther PD, Stott EJ. Viral contamination of bovine foetal serum 
and cell cultures. Nature. 1977;266(5605):835–7.
 9. Tonti GA, Mannello F. From bone marrow to therapeutic applications: dif‑
ferent behaviour and genetic/epigenetic stability during mesenchymal 
stem cell expansion in autologous and foetal bovine sera? Int J Dev Biol. 
2008;52(8):1023–32. doi:10.1387/ijdb.082725gt.
 10. Kozasa T, Aoki H, Nakajima N, Fukusho A, Ishimaru M, Nakamura S. 
Methods to select suitable fetal bovine serum for use in quality control 
assays for the detection of adventitious viruses from biological products. 
Biologicals. 2011;39(4):242–8. doi:10.1016/j.biologicals.2011.06.001.
 11. Nikfarjam L, Farzaneh P. Prevention and detection of Mycoplasma con‑
tamination in cell culture. Cell J. 2012;13(4):203–12.
 12. Brunner D, Frank J, Appl H, Schoffl H, Pfaller W, Gstraunthaler G. Serum‑
free cell culture: the serum‑free media interactive online database. Altex. 
2010;27(1):53–62.
 13. Gstraunthaler G, Lindl T, van der Valk J. A plea to reduce or replace fetal 
bovine serum in cell culture media. Cytotechnology. 2013;65(5):791–3. 
doi:10.1007/s10616‑013‑9633‑8.
 14. Guideline on the use of bovine serum in the manufacture of human 
biological medicinal products. EMA/CHMP/BWP/457920/2012rev1 Com‑
mittee for Medicinal Products for Human Use (CHMP); 2013.
 15. Note for guidance on minimising the risk of transmitting animal 
spongiform encephalopathy agents via human and veterinary medicinal 
products. EMA/410/01rev3, 2011/C 73; 2011.
 16. Schallmoser K, Rohde E, Reinisch A, Bartmann C, Thaler D, Drexler C, et al. 
Rapid large‑scale expansion of functional mesenchymal stem cells from 
unmanipulated bone marrow without animal serum. Tissue Eng Part C 
Method. 2008;14(3):185–96. doi:10.1089/ten.tec.2008.0060.
 17. Doucet C, Ernou I, Zhang Y, Llense JR, Begot L, Holy X, et al. Platelet lysates 
promote mesenchymal stem cell expansion: a safety substitute for animal 
serum in cell‑based therapy applications. J Cell Physiol. 2005;205(2):228–
36. doi:10.1002/jcp.20391.
 18. Schallmoser K, Bartmann C, Rohde E, Reinisch A, Kashofer K, Stadelmeyer 
E, et al. Human platelet lysate can replace fetal bovine serum for clinical‑
scale expansion of functional mesenchymal stromal cells. Transfusion. 
2007;47(8):1436–46. doi:10.1111/j.1537‑2995.2007.01220.x (TRF01220 
[pii]).
 19. Bieback K, Hecker A, Kocaomer A, Lannert H, Schallmoser K, Strunk D, 
et al. Human alternatives to fetal bovine serum for the expansion of mes‑
enchymal stromal cells from bone marrow. Stem Cell. 2009;27(9):2331–
41. doi:10.1002/stem.139.
 20. Kinzebach S, Dietz L, Kluter H, Thierse HJ, Bieback K. Functional and 
differential proteomic analyses to identify platelet derived factors 
affecting ex vivo expansion of mesenchymal stromal cells. BMC Cell Biol. 
2013;14:48. doi:10.1186/1471‑2121‑14‑48 1471-2121-14-48 [pii].
 21. Casu B, Lindahl U. Structure and biological interactions of heparin and 
heparan sulfate. Adv Carbohydr Chem Biochem. 2001;57:159–206.
 22. Spivak‑Kroizman T, Lemmon MA, Dikic I, Ladbury JE, Pinchasi D, Huang J, 
et al. Heparin‑induced oligomerization of FGF molecules is responsible 
for FGF receptor dimerization, activation, and cell proliferation. Cell. 
1994;79(6):1015–24. doi:10.1016/0092‑8674(94)90032‑9.
 23. Flint N, Cove FL, Evans GS. Heparin stimulates the proliferation of intesti‑
nal epithelial cells in primary culture. J Cell Sci. 1994;107(Pt 2):401–11.
 24. Wu WK, Shin VY, Ye YN, Wong HP, Huang FY, Hui MK, et al. Heparin 
increases human gastric carcinoma cell growth. Anticancer Res. 
2006;26(1A):439–43.
 25. Thornton SC, Mueller SN, Levine EM. Human endothelial cells: use 
of heparin in cloning and long‑term serial cultivation. Science. 
1983;222(4624):623–5.
Page 10 of 10Laner‑Plamberger et al. J Transl Med  (2015) 13:354 
 26. Hemeda H, Kalz J, Walenda G, Lohmann M, Wagner W. Heparin 
concentration is critical for cell culture with human platelet lysate. 
Cytotherapy. 2013;15(9):1174–81. doi:10.1016/j.jcyt.2013.05.006 (S1465-
3249(13)00516-1 [pii]).
 27. Hemeda H, Giebel B, Wagner W. Evaluation of human platelet lysate 
versus fetal bovine serum for culture of mesenchymal stromal cells. 
Cytotherapy. 2014;16(2):170–80. doi:10.1016/j.jcyt.2013.11.004 (S1465-
3249(13)00777-9 [pii]).
 28. Seeger FH, Rasper T, Fischer A, Muhly‑Reinholz M, Hergenreider E, 
Leistner DM, et al. Heparin disrupts the CXCR4/SDF‑1 axis and impairs 
the functional capacity of bone marrow‑derived mononuclear cells 
used for cardiovascular repair. Circ Res. 2012;111(7):854–62. doi:10.1161/
CIRCRESAHA.112.265678.
 29. Almeida CR, Vasconcelos DP, Goncalves RM, Barbosa MA. Enhanced mes‑
enchymal stromal cell recruitment via natural killer cells by incorporation 
of inflammatory signals in biomaterials. J R Soc Interface. 2012;9(67):261–
71. doi:10.1098/rsif.2011.0357.
 30. Copland IB, Garcia MA, Waller EK, Roback JD, Galipeau J. The effect of 
platelet lysate fibrinogen on the functionality of MSCs in immunotherapy. 
Biomaterials. 2013;34(32):7840–50. doi:10.1016/j.biomaterials.2013.06.050 
(S0142-9612(13)00765-5 [pii]).
 31. Mojica‑Henshaw MP, Jacobson P, Morris J, Kelley L, Pierce J, Boyer 
M, et al. Serum‑converted platelet lysate can substitute for fetal 
bovine serum in human mesenchymal stromal cell cultures. Cyto‑
therapy. 2013;15(12):1458–68. doi:10.1016/j.jcyt.2013.06.014 (S1465-
3249(13)00598-7 [pii]).
 32. Janmey PA. Kinetics of formation of fibrin oligomers. I Theor Biopolym. 
1982;21(11):2253–64. doi:10.1002/bip.360211112.
 33. Janmey PA, Schliwa M. Rheology. Curr Biol. 2008;18(15):R639–41. 
doi:10.1016/j.cub.2008.05.001.
 34. Reinisch A, Strunk D. Isolation and animal serum free expansion of human 
umbilical cord derived mesenchymal stromal cells (MSCs) and endothe‑
lial colony forming progenitor cells (ECFCs). J Vis Exp. 2009;32:1525. 
doi:10.3791/1525.
 35. Rohban R, Reinisch A, Etchart N, Schallmoser K, Hofmann NA, Szoke 
K, et al. Identification of an effective early signaling signature during 
neo‑vasculogenesis in vivo by ex vivo proteomic profiling. PLoS One. 
2013;8(6):e66909. doi:10.1371/journal.pone.0066909.
 36. Reinisch A, Etchart N, Thomas D, Hofmann NA, Fruehwirth M, Sinha S, 
et al. Epigenetic and in vivo comparison of diverse MSC sources reveals 
an endochondral signature for human hematopoietic niche formation. 
Blood. 2015;125(2):249–60. doi:10.1182/blood‑2014‑04‑572255 (blood-
2014-04-572255 [pii]).
 37. Dell’Orco RT, Mertens JG, Kruse PF Jr. Doubling potential, calendar 
time, and senescence of human diploid cells in culture. Exp Cell Res. 
1973;77(1):356–60.
 38. Connick P, Kolappan M, Crawley C, Webber DJ, Patani R, Michell 
AW, et al. Autologous mesenchymal stem cells for the treatment of 
secondary progressive multiple sclerosis: an open‑label phase 2a 
proof‑of‑concept study. Lancet Neurol. 2012;11(2):150–6. doi:10.1016/
S1474‑4422(11)70305‑2.
 39. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf RK, Schulman SP, et al. A 
randomized, double‑blind, placebo‑controlled, dose‑escalation study 
of intravenous adult human mesenchymal stem cells (prochymal) after 
acute myocardial infarction. J Am Coll Cardiol. 2009;54(24):2277–86. 
doi:10.1016/j.jacc.2009.06.055.
 40. Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, et al. Mesenchy‑
mal stem cells for treatment of steroid‑resistant, severe, acute graft‑
versus‑host disease: a phase II study. Lancet. 2008;371(9624):1579–86. 
doi:10.1016/S0140‑6736(08)60690‑X.
 41. Otsuru S, Gordon PL, Shimono K, Jethva R, Marino R, Phillips CL, et al. 
Transplanted bone marrow mononuclear cells and MSCs impart 
clinical benefit to children with osteogenesis imperfecta through 
different mechanisms. Blood. 2012;120(9):1933–41. doi:10.1182/
blood‑2011‑12‑400085.
 42. Bottio T, Pittarello G, Bonato R, Fagiolo U, Gerosa G. Life‑threatening 
anaphylactic shock caused by porcine heparin intravenous infusion 
during mitral valve repair. J thorac cardiovasc surg. 2003;126(4):1194–5. 
doi:10.1016/S0022.
 43. Harada A, Tatsuno K, Kikuchi T, Takahashi Y, Sai S, Murakami Y, et al. Use of 
bovine lung heparin to obviate anaphylactic shock caused by porcine 
gut heparin. Ann thorac surg. 1990;49(5):826–7.
 44. Huang Q, Xu T, Wang GY, Huang JF, Xia H, Yin R, et al. Species‑specific 
identification of ruminant components contaminating industrial crude 
porcine heparin using real‑time fluorescent qualitative and quan‑
titative PCR. Anal Bioanal Chem. 2012;402(4):1625–34. doi:10.1007/
s00216‑011‑5590‑2.
 45. Liu H, Zhang Z, Linhardt RJ. Lessons learned from the contamination of 
heparin. Nat Prod Rep. 2009;26(3):313–21. doi:10.1039/b819896a.
 46. Gheno G, Savarino C, Vellar S, Cinetto L. Heparin‑induced life‑threatening 
hyperkalemia. Ann Ital Med Int. 2002;17(1):51–3.
 47. Linkins LA. Heparin induced thrombocytopenia. Bmj. 2015;350:g7566. 
doi:10.1136/bmj.g7566.
 48. Blossom DB, Kallen AJ, Patel PR, Elward A, Robinson L, Gao G, et al. Out‑
break of adverse reactions associated with contaminated heparin. N Engl 
J Med. 2008;359(25):2674–84. doi:10.1056/NEJMoa0806450.
 49. Farrugia BL, Lord MS, Melrose J, Whitelock JM. Can We Produce Heparin/
Heparan Sulfate Biomimetics Using “Mother‑Nature” as the Gold Stand‑
ard? Molecules. 2015;20(3):4254–76. doi:10.3390/molecules20034254.
 50. Barak H, Huh SH, Chen S, Jeanpierre C, Martinovic J, Parisot M, et al. FGF9 
and FGF20 maintain the stemness of nephron progenitors in mice and 
man. Dev Cell. 2012;22(6):1191–207. doi:10.1016/j.devcel.2012.04.018 
(S1534-5807(12)00195-5 [pii]).
 51. Ho W, Tawil B, Dunn JC, Wu BM. The behavior of human mesenchymal 
stem cells in 3D fibrin clots: dependence on fibrinogen concentra‑
tion and clot structure. Tissue Eng. 2006;12(6):1587–95. doi:10.1089/
ten.2006.12.1587.
 52. Kanatani M, Sugimoto T, Kanzawa M, Yano S, Chihara K. High extracellular 
calcium inhibits osteoclast‑like cell formation by directly acting on the 
calcium‑sensing receptor existing in osteoclast precursor cells. Biochem 
Biophys Res Commun. 1999;261(1):144–8. doi:10.1006/bbrc.1999.0932 
(S0006-291X(99)90932-4 [pii]).
 53. Castiglia S, Mareschi K, Labanca L, Lucania G, Leone M, Sanavio F, et al. 
Inactivated human platelet lysate with psoralen: a new perspective 
for mesenchymal stromal cell production in good manufacturing 
practice conditions. Cytotherapy. 2014;16(6):750–63. doi:10.1016/j.
jcyt.2013.12.008.
 54. Walker D, Jacobe H. Phototherapy in the age of biologics. Semin Cutan 
Med Surg. 2011;30(4):190–8. doi:10.1016/j.sder.2011.08.004.
 55. Kaiser‑Guignard J, Canellini G, Lion N, Abonnenc M, Osselaer JC, Tissot 
JD. The clinical and biological impact of new pathogen inactivation 
technologies on platelet concentrates. Blood Rev. 2014;28(6):235–41. 
doi:10.1016/j.blre.2014.07.005.
 56. Prudent M, D’Alessandro A, Cazenave JP, Devine DV, Gachet C, Greinacher 
A, et al. Proteome changes in platelets after pathogen inactivation–
an interlaboratory consensus. Transfus Med Rev. 2014;28(2):72–83. 
doi:10.1016/j.tmrv.2014.02.002.
 57. Gombold J, Karakasidis S, Niksa P, Podczasy J, Neumann K, Richardson J, 
et al. Systematic evaluation of in vitro and in vivo adventitious virus assays 
for the detection of viral contamination of cell banks and biological prod‑
ucts. Vaccine. 2014;32(24):2916–26. doi:10.1016/j.vaccine.2014.02.021.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
